MARKET

CAPR

CAPR

Capricor Therapeutics Inc
NASDAQ
26.13
-4.28
-14.06%
Opening 12:06 06/26 EDT
OPEN
27.20
PREV CLOSE
30.40
HIGH
27.40
LOW
25.63
VOLUME
1.47M
TURNOVER
--
52 WEEK HIGH
40.37
52 WEEK LOW
4.300
MARKET CAP
1.51B
P/E (TTM)
-11.2949
1D
5D
1M
3M
1Y
5Y
1D
FDA Advisory Panel To Review Capricor's Deramiocel BLA In DMD
NASDAQ · 9h ago
BUZZ-Capricor tumbles as FDA panel meet for Duchenne cell therapy adds risk worries
Reuters · 9h ago
Capricor Therapeutics to face FDA advisory panel review of deramiocel BLA in Duchenne muscular dystrophy
PUBT · 10h ago
Capricor announces FDA advisory committee meeting to review Deramiocel BLA
TipRanks · 10h ago
Capricor Therapeutics Announces FDA's Cellular, Tissue, And Gene Therapies Advisory Committee Intends To Call Advisory Committee Meeting To Discuss Capricor's BLA Of Deramiocel For Duchenne Muscular Dystrophy Treatment
Benzinga · 10h ago
CAPRICOR THERAPEUTICS - DERAMIOCEL BLA PDUFA TARGET ACTION DATE SET FOR AUGUST 22, 2026
Reuters · 10h ago
Capricor falls as FDA sets up AdCom meeting to review Duchenne therapy
Seeking Alpha · 11h ago
Capricor presents five-year data from HOPE-2 open-label extension study
TipRanks · 11h ago
More
About CAPR
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program focuses on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, Deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. The clinical development program for Deramiocel has focused primarily on adolescents and young adults with DMD, including many patients who are non-ambulatory and experiencing progressive cardiac and skeletal muscle decline. Its StealthX exosome platform program consists of engineered exosomes for vaccine and therapeutic development. The StealthX vaccine is a proprietary vaccine developed internally utilizing exosomes that were engineered to express either spike or nucleocapsid proteins on the surface.

Webull offers Capricor Therapeutics Inc stock information, including NASDAQ: CAPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CAPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CAPR stock methods without spending real money on the virtual paper trading platform.